Drug Profile
Research programme: small-interfering RNA therapeutics - Arcturus Therapeutics/Takeda
Alternative Names: LUNAR-GI; LUNAR-NASHLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (Parenteral)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (Parenteral)
- 06 Dec 2016 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)